报告人：Véronique Perrier

时间：2016.07.15下午14:00-15:30

地点：东十一楼221

 

报告人简介：

Dr Véronique Perrier obtained her Ph.D in Biochemistry and Biophysics in 1997 at the Pasteur Institute of Paris, on the structural role of zinc in bacterial adenylate kinases. After her Ph.D, she joined the laboratory of Dr Stanley Prusiner (Nobel Prize of Medicine 1997) at the University of California San Francisco (UCSF) to work on prion diseases, and the new concept of infectious prion protein. In Prusiner’s laboratory, she developed a drug screening assay on prion infected cells and identified dominant negative mimetic drugs with anti-prion properties (Perrier et al., PNAS 2000). She also generated dominant negative transgenic mice that were resistant to prion inoculation, allowing to understand why some polymorphisms in prion protein are resistant to prion infection in human and animal populations (Perrier et al., PNAS 2002). In 2000, she got a position as a junior scientist at the CNRS and joined the Institute of Human Genetics in Montpellier, to work on prion diseases in the team of Dr. Sylvain Lehmann. Her main project was to developed a gene therapy strategy based on lentiviral vectors carrying dominant negative polymorphisms (Crozet et al., J. Cell Science, 2004 ; Thermofisher Scientific Biotherapy Prize 2008). Since 2005, she is a senior scientist in the Inserm laboratory of Dr. Jean-Michel Verdier located at the University of Montpellier. She developed a new diagnosis assay for detection of all prions forms (PK sensitive and PK resistant), based on aggregation of prions consecutive to interaction with small molecules that she identified (Ayrolles-Torro et al., J. Neurosci. 2011 ; Imberdis et al., Molecular Neurodegeneration 2016). Currently, Dr Véronique Perrier is collaborating with Blood Transfusion laboratory (Transdiag laboratory, Montpellier) to develop prions retention filters and detection of prions in human blood (2 patents). Besides, she has recently showed an interest towards pesticides and their potential role as risk factors in neurodegenerative diseases. Her works are focused on the effect of an analog of alpha-terthienyl, an organic pesticide, and several commercialized anti-fungicides on various mice models of neurodegenerative diseases as prions and Alzheimer’s diseases.